Last reviewed · How we verify
Ofatumumab combined with daratumumab
Ofatumumab and daratumumab are monoclonal antibodies that work synergistically to target and eliminate malignant B cells and plasma cells by binding to CD20 and CD38 respectively, triggering immune-mediated cell death.
Ofatumumab and daratumumab are monoclonal antibodies that work synergistically to target and eliminate malignant B cells and plasma cells by binding to CD20 and CD38 respectively, triggering immune-mediated cell death. Used for Multiple myeloma (in combination regimens), Chronic lymphocytic leukemia (CLL), B-cell non-Hodgkin lymphoma.
At a glance
| Generic name | Ofatumumab combined with daratumumab |
|---|---|
| Sponsor | The First People's Hospital of Changzhou |
| Drug class | Monoclonal antibody combination |
| Target | CD20 (ofatumumab) and CD38 (daratumumab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ofatumumab is a fully human anti-CD20 monoclonal antibody that binds to CD20 expressed on B cells and induces B-cell lysis through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Daratumumab is an anti-CD38 monoclonal antibody that targets CD38 on plasma cells and malignant B cells, inducing apoptosis and immune activation. The combination leverages dual targeting of complementary antigens to enhance anti-tumor efficacy in hematologic malignancies.
Approved indications
- Multiple myeloma (in combination regimens)
- Chronic lymphocytic leukemia (CLL)
- B-cell non-Hodgkin lymphoma
Common side effects
- Infusion-related reactions
- Neutropenia
- Anemia
- Thrombocytopenia
- Infections
- Fatigue
Key clinical trials
- Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: